PUBLIKACJE, BADANIA MEDYCYNA MITOCHONDRIALNA

„Medycyna mitochondrialna. Nowatorska metoda na pozornie nieuleczalne choroby”

Autor: A. Schemionek, B. Kuklinski

W książce znajdziesz szczegółowe dane dotyczące najczęściej występujących schorzeń oraz informacje, jak je pokonać dzięki mitochondriom, czyli centrom energetycznym komórek. Autor szczegółowo opisuje wpływ leczniczych głodówek i znaczenie właściwego wypoczynku. Podaje ważne składniki odżywcze i ich wpływ na mitochondria oraz wyjaśnia, dlaczego warto rozważyć przejście na dietę paleo. Poznaj dowody na skuteczność terapii mitochondrialnej w zwalczaniu ADHD, fibromialgii, cukrzycy typu 2, depresji, problemów skórnych i chorób oczu. Jest również efektywna przy dolegliwościach układu krążenia i oddechowego, migrenach i bólach menstruacyjnych, schorzeniach neurodegeneracyjnych, chorobach nerek i narządów trawiennych oraz nowotworach.
Nie ma chorób nieuleczalnych!

Medycyna mitochondrialna
http://www.czytelniamedyczna.pl/3090,medycyna-mitochondrialna.html

„Masz tę moc … w mitochondriach”
https://www.euroimmundna.pl/masz-te-moc-w-mitochondriach/

„Koniec ze zmarszczkami i wypadaniem włosów! Naukowcy powstrzymali efekt starzenia”
https://zdrowie.radiozet.pl/Uroda/Skora-wlosy-paznokcie/Zmarszczki-i-wypadanie-wlosow-poskromione!-Powstrzymano-efekt-starzenia

„Sport to nie zawsze zdrowie – zadbaj o mitochondria”
https://mito-med.pl/artykul/sport-to-nie-zawsze-zdrowie-zadbaj-o-mitochondria

„Mitochondrialne starzenie się skóry. Czy można je zatrzymać?”
https://cnb.drirenaeris.com/wp-content/uploads/2020/06/mitochondria-pl-monika-krzyzostan.pdf

„Zmiany w mitochondriach – przyczyną starzenia się skóry i całego organizmu”
https://biotechnologia.pl/kosmetologia/zmiany-w-mitochondriach-przyczyna-starzenia-sie-skory-i-calego-organizmu,3210?month=3&year=2019

„Aktywacja mitofagii – nowy sposób walki ze starzeniem skóry”
https://www.chemiaibiznes.com.pl/artykuly/aktywacja-mitofagii-nowy-sposob-walki-ze-starzeniem-skory

 „W punkt! Mitochondria”
https://www.kosmetologiawpolsce.pl/w-punkt-mitochondria/

„Na czym polega medycyna mitochondrialna?”
https://ktociewyleczy.pl/wiedza/leczenie/terapie-naturalne/4046-na-czym-polega-medycyna-mitochondrialna

„Jak działają nasze elektrownie komórkowe, czyli mitochondria?”
https://www.polskieradio.pl/7/161/Artykul/1469176,Jak-dzialaja-nasze-elektrownie-komorkowe-czyli-mitochondria

„Awarie w komórkowych elektrowniach mają dość nieoczekiwany przebieg”
https://naukawpolsce.pl/aktualnosci/news%2C28396%2Cawarie-w-komorkowych-elektrowniach-maja-dosc-nieoczekiwany-przebieg.html

Piśmiennictwo o mitochondriach:

  1. Busch KB et al.: Mitochondrial dynamics generate equal distribution but patchwork localization of respiratory Complex I. Mol Membr Biol 2006; 23: 509-20.
  2. Kotulska A, Kucharz EJ: Miopatie mitochondrialne. Terapia 2004; 5(152): 43-8.
  3. Genova ML, Bianchi C, Lenaz G: Supercomplex organization of the mitochondrial respiratory chain and the role of the Coenzyme Q pool: pathophysiological implications. Biofactors 2005; 25: 5-20.
  4. Czarna M, Jarmuszkiewicz W: Role of mitochondria in reactive oxygen species generation and removal; relevance to signaling and programmed cell death. Postepy Biochem 2006; 52: 145-56.
  5. Stone JR, Yang S: Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 2006; 8: 243-70.
  6. Newmeyer DD, Ferguson-Miller S: Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003; 112: 481-90.
  7. Gradzka I: Mechanisms and regulation of the programmed cell death. Postępy Biochem 2006; 52: 157-65.
  8. Orrenius S, Gogvadze V, Zhivotovsky B: Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 2007; 47: 143-83.
  9. Wojtczak L, Zabłocki K: Mitochondria w życiu, chorobie i śmierci komórki. Postepy Biochem 2008; 54: 129-41.
  10. Dyall SD, Brown MT, Johnson PJ: Ancient invasions: from endosymbionts to organelles. Science 2004; 304: 253-7.
  11. Legros F et al.: Organization and dynamics of human mitochondrial DNA. J Cell Sci 2004; 117: 2653-62.
  12. Anderson S et al.: Sequence and organization of the human mitochondrial genome. Nature 1981; 290: 457-65.
  13. Pfanner N, Geissler A: Versatility of the mitochondrial protein import machinery. Nat Rev Mol Cell Biol 2001; 2: 339-49.
  14. Holt IJ, Lorimer HE, Jacobs HT: Coupled leading- and lagging-strand synthesis of mammalian mitochondrial DNA. Cell 2000; 100: 515-24.
  15. Brown TA et al.: Replication of mitochondrial DNA occurs by strand displacement with alternative light-strand origins, not via a strand-coupled mechanism. Genes Dev 2005; 19: 2466-76.
  16. Montoya J et al.: Identification of initiation sites for heavy-strand and light-strand transcription in human mitochondrial DNA. Proc Natl Acad Sci U S A 1982; 79: 7195-9.
  17. Asin-Cayuela J, Gustafsson CM: Mitochondrial transcription and its regulation in mammalian cells. Trends Biochem Sci 2007; 32: 111-7.
  18. Bonawitz ND, Clayton DA, Shadel GS: Initiation and beyond: multiple functions of the human mitochondrial transcription machinery. Mol Cell 2006; 24: 813-25.
  19. Wallace DC: Mitochondrial DNA sequence variation in human evolution and disease. Proc Natl Acad Sci U S A 1994; 91: 8739-46.
  20. Tully G et al.: Considerations by the European DNA profiling (EDNAP) group on the working practices, nomenclature and interpretation of mitochondrial DNA profiles. Forensic Sci Int 2001; 124: 83-91.
  21. Cadet J et al.: Oxidative damage to DNA: formation, measurement, and biological significance. Rev Physiol Biochem Pharmacol 1997; 131: 1-87.
  22. Coskun PE, Beal MF, Wallace DC: Alzheimer´s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A 2004; 101: 10726-31.
  23. Schwartz M, Vissing J: Paternal inheritance of mitochondrial DNA. N Engl J Med 2002; 347: 576-80.
  24. Bandelt HJ et al.: More evidence for non-maternal inheritance of mitochondrial DNA? J Med Genet 2005; 42: 957-60.
  25. Macaulay V et al.: The emerging tree of West Eurasian mtDNAs: a synthesis of control-region sequences and RFLPs. Am J Hum Genet 1999; 64: 232-49.
  26. Kivisild T et al.: The role of selection in the evolution of human mitochondrial genomes. Genetics 2006; 172: 373-87.
  27. Mishmar D et al.: Natural selection shaped regional mtDNA variation in humans. Proc Natl Acad Sci U S A 2003; 100: 171-6.
  28. Ruiz-Pesini E et al.: Effects of purifying and adaptive selection on regional variation in human mtDNA. Science 2004; 303: 223-6.
  29. Wallace DC: A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005; 39: 359-407.
  30. Ostrowski J: Molecular medicine of the future-applications and pitfalls. Acta Pol Pharm 2006; 63: 329-32.
  31. Hall WD, Morley KI, Lucke JC: The prediction of disease risk in genomic medicine. EMBO Rep 2004; 5 Spec No: S22-6.
  32. DiMauro S: The many faces of mitochondrial diseases. Mitochondrion 2004; 4: 799-807.
  33. Luft R et al.: A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 1962; 41: 1776-804.
  34. Trebinska A, Golik P: Choroby mitochondrialne wywołane zaburzeniami w komunikacji między genomem jądrowym i organellarnym. Postępy Biochem 2004; 50: 45-56.
  35. Filosto M, Mancuso M: Mitochondrial diseases: a nosological update. Acta Neurol Scand 2007; 115: 211-21.
  36. Wong LJ: Diagnostic challenges of mitochondrial DNA disorders. Mitochondrion 2007; 7: 45-52.
  37. DiMauro S: Mitochondrial DNA medicine. Biosci Rep 2007; 27: 5-9.
  38. Raule N et al.: Association studies on human mitochondrial DNA: methodological aspects and results in the most common age-related diseases. Mitochondrion 2007; 7: 29-38.
  39. Potargowicz E et al.: Mitochondria jako źródło reaktywnych form tlenu. Postepy Hig Med Dosw (Online) 2005; 59: 259-66.
  40. Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7: 97-110.
  41. Brandon M, Baldi P, Wallace DC: Mitochondrial mutations in cancer. Oncogene 2006; 25: 4647-62.
  42. Parrella P et al.: Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res 2001; 61: 7623-6.
  43. Richard SM et al.: Nuclear and mitochondrial genome instability in human breast cancer. Cancer Res 2000; 60: 4231-7.
  44. Tseng LM et al.: Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer 2006; 45: 629-38.
  45. Zhu W et al.: Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis 2005; 26: 145-52.
  46. Parr RL et al.: Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 2006; 8: 312-9.
  47. Petros JA et al.: mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A 2005; 102: 719-24.
  48. Kose K et al.: Somatic mutations of mitochondrial DNA in digestive tract cancers. J Gastroenterol Hepatol 2005; 20: 1679-84.
  49. Sui G et al.: Mitochondrial DNA mutations in preneoplastic lesions of the gastrointestinal tract: a biomarker for the early detection of cancer. Mol Cancer 2006; 5: 73.
  50. Wu CW et al.: Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer 2005; 44: 19-28.
  51. Zhao YB et al.: Mutation in D-loop region of mitochondrial DNA in gastric cancer and its significance. World J Gastroenterol 2005; 11: 3304-6.
  52. Abnet CC et al.: Control region mutations and the „common deletion” are frequent in the mitochondrial DNA of patients with esophageal squamous cell carcinoma. BMC Cancer 2004; 4: 30.
  53. Tan DJ et al.: Significance of somatic mutations and content alteration of mitochondrial DNA in esophageal cancer. BMC Cancer 2006; 6: 93.
  54. Nishikawa M et al.: Somatic mutation of mitochondrial DNA in cancerous and noncancerous liver tissue in individuals with hepatocellular carcinoma. Cancer Res 2001; 61: 1843-5.
  55. Van Trappen PO et al.: Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer. Gynecol Oncol 2007; 104: 129-33.
  56. Bonora E et al.: Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 2006; 66: 6087-96.
  57. Maximo V et al.: Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 2002; 160: 1857-65.
  58. He L et al.: Somatic mitochondrial DNA mutations in adult-onset leukaemia. Leukemia 2003; 17: 2487-91.
  59. Yao YG et al.: Mitochondrial DNA sequence variation in single cells from leukemia patients. Blood 2007; 109: 756-62.
  60. Ha PK et al.: Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res 2002; 8: 2260-5.
  61. Mithani SK et al.: Mitochondrial mutations are a late event in the progression of head and neck squamous cell cancer. Clin Cancer Res 2007; 13: 4331-5.
  62. Darvishi K et al.: Mitochondrial DNA G10398A polymorphism imparts maternal Haplogroup N a risk for breast and esophageal cancer. Cancer Lett 2007; 249: 249-55.
  63. Booker LM et al.: North American white mitochondrial haplogroups in prostate and renal cancer. J Urol 2006; 175: 468-72; discussion 72-3.
  64. Salas A et al.: A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Med 2005; 2: e296.
  65. Zanssen S, Schon EA. Mitochondrial DNA mutations in cancer. PLoS Med 2005; 2: e401.
  66. Czarnecka AM et al.: Cancer as a „Mitochondriopathy”. J Cancer Mol 2007; 3: 71-9.
  67. Kelley DE et al.: Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51: 2944-50.
  68. Alcolado JC, Laji K, Gill-Randall R: Maternal transmission of diabetes. Diabet Med 2002; 19: 89-98.
  69. Mohlke KL et al.: Mitochondrial polymorphisms and susceptibility to type 2 diabetes-related traits in Finns. Hum Genet 2005; 118: 245-54.
  70. Poulton J et al.: Type 2 diabetes is associated with a common mitochondrial variant: evidence from a population-based case-control study. Hum Mol Genet 2002; 11: 1581-3.
  71. Sherratt EJ et al.: Mitochondrial DNA variations in patients with Type 2 (non-insulin dependent) diabetes mellitus and a Welsh control population. Mutation in brief no. 239. Online. Hum Mutat 1999; 13: 412-3.
  72. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
  73. Patrick L: Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine. Altern Med Rev 2002; 7: 276-91.
  74. Begriche K et al.: Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
  75. Caldwell SH et al.: Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 430-4.
  76. Sanyal AJ et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
  77. Pessayre D, Fromenty B: NASH: a mitochondrial disease. J Hepatol 2005; 42: 928-40.
  78. Pessayre D, Fromenty B, Mansouri A: Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol 2004; 16: 1095-105.
  79. Cortez-Pinto H et al.: Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. Jama 1999; 282: 1659-64.
  80. St-Pierre J et al.: Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem 2002; 277: 44784-90.
  81. Kushnareva Y, Murphy AN, Andreyev A: Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem J 2002; 368: 545-53.
  82. Chen J et al.: Formation of malondialdehyde adducts in livers of rats exposed to ethanol: role in ethanol-mediated inhibition of cytochrome c oxidase. Alcohol Clin Exp Res 2000; 24: 544-52.
  83. Chen J et al.: Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme subunits. Biochim Biophys Acta 1998; 1380: 336-44.
  84. Perez-Carreras M et al.: Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38: 999-1007.
  85. Kawahara H et al.: Mutation of mitochondrial DNA in livers from patients with alcoholic hepatitis and nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2007; 31: S54-60.
  86. Bender A et al.: High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38: 515-7.
  87. Kraytsberg Y et al.: Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 2006; 38: 518-20.
  88. Coskun PE, Ruiz-Pesini E, Wallace DC: Control region mtDNA variants: longevity, climatic adaptation, and a forensic conundrum. Proc Natl Acad Sci U S A 2003; 100: 2174-6.
  89. Cottrell DA et al.: Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 2001; 57: 260-4.
  90. Gu M et al.: Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci 1998; 158: 24-9.
  91. Manczak M et al.: Mitochondria are a direct site of A beta accumulation in Alzheimer´s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006; 15: 1437-49.
  92. Clark IE et al.: Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006; 441: 1162-6.
  93. Palacino JJ et al.: Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004; 279: 18614-22.
  94. Andres-Mateos E et al.: DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A 2007; 104: 14807-12.
  95. Ghezzi D et al.: Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson´s disease in Italians. Eur J Hum Genet 2005; 13: 748-52.
  96. Autere J et al.: Mitochondrial DNA polymorphisms as risk factors for Parkinson´s disease and Parkinson´s disease dementia. Hum Genet 2004; 115: 29-35.
  97. Ross OA et al.: mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson´s disease in the Irish. Exp Gerontol 2003; 38: 397-405.
  98. Chinnery PF et al.: Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies. Neurology 2000; 55: 302-4.
  99. Elson JL et al.: Does the mitochondrial genome play a role in the etiology of Alzheimer´s disease? Hum Genet 2006; 119: 241-54.
  100. van der Walt JM et al.: Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci Lett 2004; 365: 28-32.
  101. van der Walt JM et al.: Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 2003; 72: 804-11.
  102. Huerta C et al.: Mitochondrial DNA polymorphisms and risk of Parkinson´s disease in Spanish population. J Neurol Sci 2005; 236: 49-54.
  103. Paravicini TM, Touyz RM: NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008; 31 Suppl 2: S170-80.
  104. Vaziri ND, Rodriguez-Iturbe B: Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2: 582-93.
  105. Moukdar F et al.: Reduced antioxidant capacity and diet-induced atherosclerosis in uncoupling protein-2-deficient mice. J Lipid Res 2008;
  106. Hill MF, Singal PK: Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 1996; 148: 291-300.
  107. Ide T et al.: Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res 2000; 86: 152-7.
  108. Andrienko T et al.: Metabolic consequences of functional complexes of mitochondria, myofibrils and sarcoplasmic reticulum in muscle cells. J Exp Biol 2003; 206: 2059-72.
  109. Ide T et al.: Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001; 88: 529-35.
  110. Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC: Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat Res 1992; 275: 169-80.
  111. Kajander OA, Karhunen PJ, Jacobs HT: The relationship between somatic mtDNA rearrangements, human heart disease and aging. Hum Mol Genet 2002; 11: 317-24.
  112. Lebrecht D et al.: Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 2003; 108: 2423-9.
  113. De Benedictis G et al.: Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. Faseb J 1999; 13: 1532-6.
  114. Ross OA et al.: Mitochondrial DNA polymorphism: its role in longevity of the Irish population. Exp Gerontol 2001; 36: 1161-78.
  115. Niemi AK et al.: Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. Hum Genet 2003; 112: 29-33.
  116. Dato S et al.: Association of the mitochondrial DNA haplogroup J with longevity is population specific. Eur J Hum Genet 2004; 12: 1080-2.
  117. Penta JS et al.: Mitochondrial DNA in human malignancy. Mutat Res 2001; 488: 119-33.
  118. Fuku N et al.: Mitochondrial haplogroup N9a confers resistance against type 2 diabetes in Asians. Am J Hum Genet 2007; 80: 407-15.
  119. Birch-Machin MA: Using mitochondrial DNA as a biosensor of early cancer development. Br J Cancer 2005; 93: 271-2.
  120. Aikhionbare FO, et al.: Is cumulative frequency of mitochondrial DNA variants a biomarker for colorectal tumor progression? Mol Cancer 2004; 3: 30.
  121. Wong LJ, Boles RG: Mitochondrial DNA analysis in clinical laboratory diagnostics. Clin Chim Acta 2005; 354: 1-20.
  122. Forster P: To err is human. Ann Hum Genet 2003; 67: 2-4.
  123. Piechota J et al.: Comparison between the Polish population and European populations on the basis of mitochondrial morphs and haplogroups. Acta Biochim Pol 2004; 51: 883-95.
  124. Roff DA, Bentzen P: The statistical analysis of mitochondrial DNA polymorphisms: chi 2 and the problem of small samples. Mol Biol Evol 1989; 6: 539-45.
Nowsze CYTRYNA
Back to list
Starsze HISTORIA